William Sun

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · New England Journal of Medicine · 2012 · 2K citations · Full text

Importance of the Intracellular Domain of NR2 Subunits for NMDA Receptor Function In Vivo

Rolf Sprengel, Bettina Suchanek, Carla Amico et al. · Cell · 1998 · 460 citations · Full text

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · Haematologica · 2015 · 325 citations · Full text

The 11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy

Julio Rosenstock, Salomon Banarer, Vivian Fonseca et al. · Diabetes Care · 2010 · 309 citations · Full text

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Srđan Verstovšek, Jason Gotlib, Ruben A. Mesa et al. · Journal of Hematology & Oncology · 2017 · 286 citations · Full text